




Presence in more than 80 countries
Medicinal products sold in over 125 countries



28 production sites in 16 countries




6 research centres in the USA, UK, Sweden & China

\$58.7bn total revenue
\$14.2bn invested in research



OUR TREATMENT AREAS

ONCOLOGY	BIOPHARMACEUTICALS	
	Cardiovascular, kidney and metabolic diseases	Respiratory diseases and immunology
		 Infectious diseases
RARE DISEASES		



In Zug since 1999

In Baar since 2018

In Switzerland since 1976



57 % women



43 % men

4 months equal parental leave



Awarded "Great Place to Work" for the seventh time



About 280 employees from around 20 nations



93% of our employees rate us as a "Great Place to Work"



Over 275'000 patients being treated with AstraZeneca medicines



33 medicinal products on the market



Medicines effective against 20 diseases


Over 1'700'000 packs of medicinal products sold



STADE DE SUISSE

OVER CHF 240 MILLION TURNOVER

AMONG THE 10 TOP-SELLING SWISS PHARMACEUTICAL COMPANIES



35 clinical and real-world evidence studies with patients

11.25 million CHF Investment in research & development



Over 40 partnerships and lighthouse projects with leading healthcare organisations



20 study centres



2028

Approval of 40 new therapies expected by end of 2028.



CURRENTLY BEING RESEARCHED GLOBALLY



20 new molecules



197 new therapeutic approaches

GLOBAL VISION: CO₂ NEGATIVE BY 2045



CO₂

Already today in Switzerland:



100 % renewable energies in the AZ building



100 % electric cars in the vehicle fleet